Retatrutide 40mg
Alluvi Healthcare's premium Retatrutide formulation — a triple-agonist peptide targeting GLP-1, GIP and glucagon receptors.
- Triple-agonist activity across GLP-1, GIP and glucagon receptors
- GMP-certified manufacturing
- 40mg pen — supplied as 4 doses of 10mg
- Store in a refrigerator between 2°C and 8°C
- For subcutaneous research use only
- Discreet, tracked UK-wide delivery
Secure Checkout
Cold-Chain Shipping
Tracked Delivery
Product Description
Retatrutide 40mg is a precision-manufactured, triple-agonist research peptide supplied by Alluvi Healthcare. It is formulated to act on three metabolic receptor pathways — GLP-1, GIP and glucagon — making it one of the most closely studied compounds in current metabolic research.
Each box contains a single pre-filled pen holding 40mg of Retatrutide, divided into 4 doses of 10mg, and is manufactured under Good Manufacturing Practice (GMP) certified conditions.
Why Researchers Choose This Formulation
- Consistent, batch-verified potency and purity
- GMP-certified manufacturing process
- Simple, pre-filled pen format for controlled dosing
Frequently Asked Questions
How is this different from the standard Retatrutide 40mg Pen?
This is an alternative Alluvi Healthcare batch/formulation of the same 40mg strength, manufactured under GMP-certified conditions.
How should it be stored?
Store in a refrigerator between 2°C and 8°C. Always read the package leaflet before use.
Are refunds available?
All sales are final and non-refundable once dispatched. See our Refund Policy for full details.